At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
31P-MRS and Resting State Functional Connectivity Analysis of the Effects of 5-hydroxytryptophan and Creatine for Antidepressant Augmentation in Patients With SSRI/SNRI-resistant Major Depressive Disorder
In Brief
A Phase 2 clinical trial evaluating 5-Hydroxytryptophan 100 MG, Creatine monohydrate, and 2 other interventions for Major Depressive Disorder. Completed, enrolled 43 participants across 1 site.
Detailed Summary
This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression. Subjects will be randomized between 5-HTP + placebo, creatine + placebo, and 5-HTP + creatine, for 8 weeks. The ability of the interventions to affect biomarkers associated with depression will be assessed using brain phosphorus magnetic resonance spectroscopy, functional connectivity imaging, and plasma serotonin levels.
Study Details
Timeline
Interventions
5-HTP 100mg PO BID
Creatine monohydrate 5g PO qday
placebo matched to 5-HTP
Dextrose either as loose powder (matched to creatine) or encapsulated (matched to 5-HTP)